{"title":"The effect of exogenous glutathione on meropenem susceptibility in Klebsiella pneumoniae-carbapenemases (KPC)-producing bacteria.","authors":"Dong H Kwon, Mital Vasoya, Danya Sankaranarayanan","doi":"10.1038/s41429-025-00850-7","DOIUrl":null,"url":null,"abstract":"<p><p>Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae and Pseudomonas aeruginosa, associated with systemic and hospital-acquired infections, have spread globally and pose a significant public health concern. Glutathione is a multifunctional thiol-antioxidant compound synthesized in most Gram-negative bacteria and crucial in maintaining intracellular redox homeostasis. Exogenous glutathione exhibits antibiotic properties and has differential effects on conventional antibiotics. Therefore, its effect on specific antibiotics needs to be clarified in bacterial species. In this study, we investigated the antibacterial activity of glutathione and its effect on meropenem susceptibility in KPC-producing bacteria. Two major KPC-encoding genes cloned from two different clinical KPC-producing K. pneumoniae were introduced into E. coli and P. aeruginosa. Then, the KPC-producing K. pneumoniae, E. coli, and P. aeruginosa were used for minimum inhibitory concentration (MIC), population analysis, checkerboard, and time-killing assays. The results showed that glutathione exhibited antibacterial activity at >10 mM in K. pneumoniae, E. coli, and P. aeruginosa. MIC levels of meropenem combined with 10 mM of glutathione were synergistically decreased by 8- to ≥ 256-fold in KPC-producing bacteria. Furthermore, this combination killed 100% of the KPC-producing bacteria at 2 to 4 μg mL<sup>-1</sup> of meropenem. These findings suggest that exogenous glutathione may be applicable in fighting infections caused by KPC-producing bacteria.</p>","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antibiotics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41429-025-00850-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae and Pseudomonas aeruginosa, associated with systemic and hospital-acquired infections, have spread globally and pose a significant public health concern. Glutathione is a multifunctional thiol-antioxidant compound synthesized in most Gram-negative bacteria and crucial in maintaining intracellular redox homeostasis. Exogenous glutathione exhibits antibiotic properties and has differential effects on conventional antibiotics. Therefore, its effect on specific antibiotics needs to be clarified in bacterial species. In this study, we investigated the antibacterial activity of glutathione and its effect on meropenem susceptibility in KPC-producing bacteria. Two major KPC-encoding genes cloned from two different clinical KPC-producing K. pneumoniae were introduced into E. coli and P. aeruginosa. Then, the KPC-producing K. pneumoniae, E. coli, and P. aeruginosa were used for minimum inhibitory concentration (MIC), population analysis, checkerboard, and time-killing assays. The results showed that glutathione exhibited antibacterial activity at >10 mM in K. pneumoniae, E. coli, and P. aeruginosa. MIC levels of meropenem combined with 10 mM of glutathione were synergistically decreased by 8- to ≥ 256-fold in KPC-producing bacteria. Furthermore, this combination killed 100% of the KPC-producing bacteria at 2 to 4 μg mL-1 of meropenem. These findings suggest that exogenous glutathione may be applicable in fighting infections caused by KPC-producing bacteria.
期刊介绍:
The Journal of Antibiotics seeks to promote research on antibiotics and related types of biologically active substances and publishes Articles, Review Articles, Brief Communication, Correspondence and other specially commissioned reports. The Journal of Antibiotics accepts papers on biochemical, chemical, microbiological and pharmacological studies. However, studies regarding human therapy do not fall under the journal’s scope. Contributions regarding recently discovered antibiotics and biologically active microbial products are particularly encouraged. Topics of particular interest within the journal''s scope include, but are not limited to, those listed below:
Discovery of new antibiotics and related types of biologically active substances
Production, isolation, characterization, structural elucidation, chemical synthesis and derivatization, biological activities, mechanisms of action, and structure-activity relationships of antibiotics and related types of biologically active substances
Biosynthesis, bioconversion, taxonomy and genetic studies on producing microorganisms, as well as improvement of production of antibiotics and related types of biologically active substances
Novel physical, chemical, biochemical, microbiological or pharmacological methods for detection, assay, determination, structural elucidation and evaluation of antibiotics and related types of biologically active substances
Newly found properties, mechanisms of action and resistance-development of antibiotics and related types of biologically active substances.